Sahar Emami Naeini

Sep 23, 2024 | biorxiv.org | Sahar Emami Naeini |Bidhan Bhandari |Hannah Rogers |Jules Gouron

AbstractDiabetes continues to challenge healthcare system as one of the most growing epidemics with staggering economic burden. It is estimated that 783 million by 2045 will live with diabetes worldwide, 90% of those cases are type 2 diabetes (T2D). T2D is a multifaceted disease, its treatment requires a holistic approach, beyond single target medications with high efficacy. There is a dire need to explore and invent new and effective therapeutic modalities for T2D.

Aug 26, 2024 | biorxiv.org | Bidhan Bhandari |Sahar Emami Naeini |Hannah Rogers |Sholeh Rezaei

AbstractObjective: Cannabidiol (CBD) is one of the most prominent non-psychotropic cannabinoids with known therapeutic potentials. Based on its anti-seizure efficacy, the first cannabis derived, pharmaceutical grade CBD-based medication was approved in the USA in 2018 for the treatment of seizures in patients 2 years and older.

Jul 23, 2024 | biorxiv.org | Bidhan Bhandari |Sahar Emami Naeini |Pablo Shimaoka Chagas |Hannah Rogers

AbstractIntroduction: Fentanyl and non-pharmaceutical fentanyl use have been the leading causes of opioid-induced death worldwide. Being 50 times stronger than heroin and 100 times stronger than morphine, fentanyl is a potent opioid with overdoses causing over 250,000 deaths since 2018 in the US alone. The treatment of fentanyl addiction is a complex process and a clinical challenge. There is a dire need to find other innovative and alternative modalities in the fight against fentanyl crisis.

Jun 11, 2024 | biorxiv.org | Sahar Emami Naeini |Bidhan Bhandari |Hannah Rogers |Jules Gouron

AbstractDiabetes continues to challenge healthcare system as one of the most growing epidemics with staggering economic burden. It is estimated that 783 million by 2045 will live with diabetes worldwide, 90% of those cases are type 2 diabetes (T2D). T2D is a multifaceted disease, its treatment requires a holistic approach, beyond single target medications with high efficacy. There is a dire need to explore and invent new and effective therapeutic modalities for T2D.

Jun 4, 2024 | biorxiv.org | Sahar Emami Naeini |Bidhan Bhandari |Hannah Rogers |Jules Gouron

AbstractIntroduction: Diabetes continues to challenge healthcare system as one of the most growing epidemics with staggering economic burden. It is estimated that 783 million by 2045 will live with diabetes worldwide, 90% of those cases are type 2 diabetes (T2D). T2D is a multifaceted disease, its treatment requires a holistic approach with wide range and impactful efficacy.